Helius Therapeutics is set to release drugs containing THC soon, all grown and manufactured in New Zealand.
Earlier, the country's largest licensed medicinal marijuana company was awarded a Good Manufacturing Practice (GMP) certificate from MedSafe, allowing them to produce THC medication.
2022 is a pivotal year for Helius. Achieving these milestones will enable us to bring more New Zealand-grown and manufactured products to patients in New Zealand," said Carmen Doran, CEO of Helius Therapeutics.
Last week, we announced our GACP certification. Now, we have achieved GMP certification in an additional four processes at our spacious East Auckland factory. This progress demonstrates the team collaboration culture being established at Helius," she said.
In July 2021, Helius obtained their first GMP certification and pharmaceutical manufacturing license. Since then, they have become the first company in New Zealand to launch and offer products made and grown in New Zealand. They are now the first company in New Zealand to obtain GMP certification for THC drugs.
In 2018, Helius began a rigorous and complex journey to achieve GMP certification as a startup. With international recognition and the latest approval from MedSafe meeting European standards, known as EU-GMP, this 100% New Zealand company now has potential for future export opportunities.
The GMP certification process is very thorough, and rightfully so. As we are in the business of pharmaceuticals, we cannot afford to cut corners. Helius has assembled a team of leaders with international experience in both the pharmaceutical and medicinal cannabis industries, and we have successfully achieved this level of compliance," she said.
As a leader in New Zealand's newest industry, Helius has been working with regulatory bodies from the beginning to ensure patient safety.
Carmen Doran, CEO of Helius, has been appointed to the New Zealand Medical Cannabis Council. This organization seeks to support the local industry and provide high-quality export products for patients worldwide. Doran stated that Helius has established teams and facilities to improve patients' quality of life and is dedicated to this goal.
Helius is utilizing vertical integration from the factory to the patient. Its operations link variety breeding with yield optimization, precise extraction of high-value cannabinoids, next-generation drug development, GMP production, and academic and scientific partnerships.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
